healthgenetech


Leave a comment

HEALTH Gene Technologies presents new products at Bundelkhand University in Jhansi, India

HEALTH Gene Technologies took part in an international conference on Advances in Forensic DNA technology organized by Institute of Forensic Science and Criminology at Bundelkhand University in the city of Jhansi on February 22-24.

The conference was a push for connecting academics, students, the police and new technology developers to have a joint conversation about the present state and the future advances of forensic DNA technologies in the country. As cities in India are building a number of new forensic DNA laboratories in response to rising crime rates, there is a pressing need to share experience among laboratory experts.

The presentations in the conference were primarily focused on STR forensic analysis, many sharing case experiences of sexual assault, murder, kidnapping and paternity disputes.

HEALTH Gene Technologies took the opportunity to introduce a new kit of SureID® 23comp Human DNA Identification Kit for complex kinship and paternity cases.

Forensic State Laboratory in Sagar, Madhya Pradesh State, presented own experience of working with the kit in a speech titled “Use of Alternative STR Markers in Forensic DNA Typing”. The presentation focused on three complex paternity cases that would have been difficult to solve without complementary loci kits.

For more information about HEALTH Gene Technologies’ SureID® 23comp Human DNA Identification Kit, press here : http://www.healthgenetech.net/23comp

Advertisements


Leave a comment

Health Gene Tech showcases new products at ISFG

ISFG

ISFG – the International Society of Forensic Genetics – has held its 27th Congress in Seoul, South Korea, from August 28 to September 2. The congress united scientists, industry innovators and public security actors to discuss new technologies and advances in forensic science. This year’s conference focused on seven main topics:

  1. Massively Parallel Sequencing;
  2. Population Genetics, Lineage, Ancestry, Paternity;
  3. Non-human DNA, microbiology and other MPS;
  4. Body Fluid, Touch DNA, Forensic Biology;
  5. Predictive, Biostatistics;
  6. Ethics & Legal, DNA databases, DVI;
  7. New Technologies, DNA Methods, QC.

会场

Scientific partner of Health Gene Technologies – the University of Technology Sydney and Beijing Institute of Genomics Chinese Academy of Science- presented a poster of our newest scientific collaboration with the SureID Compass kit that simultaneously detects 16 autosome STR loci and 17 Y-STR loci, and is suitable for building autosome STR and Y-STR databases.

报告

Additionally, Health Gene Technologies launched our newest product development for complex kinship testing – 23Comp. This set of non-CODIS loci provides a CPI of 1-3.0483×10E-26. It can be used as a complementary STR kit to popular commercial STR kits when complex cases need to be solved. Free product trials of 23Comp are available upon request at ausma.b@healthgenetech.com

We will meet again at ISFG’s 28th Congress in Prague in 2019!


Leave a comment

Health Gene Technologies attends 69th AACC in San Diego

This year’s AACC was one of the biggest exhibitions and conferences in the history of American Association of Clinical Chemistry.

The 69th AACC Clinical Lab Expo featured 789 exhibitors and covered 246,000 net square feet, also making this the largest show floor in AACC’s history. As of Wednesday, August 2, more than 21,300 laboratory medicine professionals and healthcare leaders had registered for the meeting, which is a 7.9% increase over meeting attendance in 2016 and the highest number of attendees that have come to the meeting in its history.

Health Gene Technologies took part in the event fourth year in a row. This exhibition focused on demonstrating the mature product of clinical diagnostics, the star of the forensic science, and the RUO products in HGT pipeline.

Respiratory pathogen infection is one of the most common clinical diseases, causing millions of mortality worldwide every year. In the global appeal to reduce the abuse of antibiotics, a clear identification of respiratory infection pathogens and then targeted treatment help to alleviate the serious problem of antibiotic abuse. Health Gene Technologies’SureX® 13 Respiratory Pathogen Multiplex Kit ​covering 11 common respiratory viruses, chlamydia and Mycoplasma pneumoniae. Compared to other products on the market, this kit has advantagesof being comprehensive, multiplex in one tube, triple quality controls, and accurate results.

World-wide epidemiological studies have shown that cervical cancer is the second most common malignant disease in women. High-risk oncogenic HPV (Human papillomavirus) types (including HPV 16 and HPV 18) are associated with 99.7% of all cervical cancers, indicating that the presence of HPV is an obligatory element in the development of cervical cancer. Persistent infection with high-risk HPV types may progress to precancerous lesions, which is the root cause of nearly all cases of cervical cancer. HGT’s SureX® HPV 25X Genotyping Kit can detect and genotype25 HPV typessimultaneously.

During the three-day exhibition, HGT attracted many visitors discussing the possible directions of follow-up work.

hdr

HGT is committed to developing and manufacturing simple, rapid and effective nucleic acid (DNA) testing solutions for molecular diagnostics, clinical research and forensic analysis.


Leave a comment

Health Gene Technologies to take part in AACC 2017, San Diego

Health Gene Technologies has taking part in the American Association for Clinical Chemistry the fourth time this year, see our previous stories 2014 2015 2016.

2017 AACC

The vision of AACC has united medical healthcare professionals over many years: “AACC is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. Our leadership in education, advocacy and collaboration helps lab professionals adapt to change and do what they do best: provide vital insight and guidance so patients get the care they need.”

This year Health Gene Technologies will be presenting our new 13 Respiratory Pathogen Multiplex Kit:

Features

  • Multiplex: Adaptable to detection of multiple pathogens simultaneously.
  • Single-tube: Perform cDNA synthesis and multiplex PCR in one tube.
  • Comprehensive: Identify 11 most common respiratory viruses, chlamydia and Mycoplasma pneumonia.
  • Sensitive: High sensitivity similar to qPCR.
  • Efficient: Perform the whole assay within 4 hrs; Hands-on time as short as 0.5 hr; Up to 192 samples within 8 hrs
  • Accurate:
  1.  Three controls monitor sample quality and the whole assay, reducing risk of false negatives
  2.  No cross-reaction with other pathogens
  3.  Efficient anti-contamination system, reducing risk of false positives
  • Objective: Normalize signaling on CE platforms by standard mix; Results output by software.
  • Compatible: Work well on oropharyngeal swabs and sputum; Perform PCR on common thermal cyclers and

CE platforms (GeXP/CEQ or ABI3130/3500).

  • Economic: Much cheaper than qPCR (for 13 pathogens detection) and liquid chip tests.

 呼吸道 英

Health Gene Technologies is looking forward to welcoming you in our booth #3857!

 


Leave a comment

SureID® 21G Human STR Identification Kit makes a debut in Emirates Forensic 2017

On April 2 – 4th Health Gene Technologies visited Emirates International Forensic Conference & Exhibition Emirates Forensic 2017 – the region’s largest event on forensics and criminology at the Dubai International Convention & Exhibition Centre. The conference invited key specialists from new technology developers to criminal police judges to share international experience through workshops, exhibitions, poster presentations and oral presentations.

HGT 1

Health Gene Technologies presented an in-depth validation study of our key product – SureID® 21G Human STR Identification Kit with our scientific collaboration partner SIMEF.

HGT 2

HGT 3

 


About Health Gene Technologies

Health Gene Technologies founded in August 2011 is focused on gene analysis, molecular diagnostics product development, as well as the production and the sales of the products. HGT boasts 2,000 square meters of molecular diagnostics R&D laboratory and a 1,000 square metre GMP standard purification plant. It employs both domestic and foreign leading molecular diagnostics and production management personnel, led by the professional R&D team.

Inspired by our motto “Health Technologies • Healthy Life” HGT commits to high standard AFA product development. The unique AFA technology is dedicated to independent R&D and production of nucleic acid molecule detection products. The products comply with leading international standards for human ID and paternity identification, infectious pathogen detection, individualized medication guide and provides the most superior molecular detection solutions.

 

For more information, please visit

https://www.facebook.com/HealthGene

https://healthgenetech.wordpress.com/

https://twitter.com/HealthGeneTech

https://www.linkedin.com/company/health-gene-technologies-co-ltd


Leave a comment

Thermo Fisher Scientific Partners with HEALTH BioMed to Support Molecular Diagnostics Development in China

CARLSBAD, Calif., and NINGBO, China– AACC 2016 – (July 28, 2016) – Thermo Fisher Scientific, the world leader in serving science, and HEALTH BioMed (HBM) today announces a collaboration to support HBM’s development of molecular diagnostic (MDx) kits for infectious disease and pharmacogenomics screening to serve the China market.

Under the terms of a strategic agreement, HBM will submit all kits it develops on the Applied Biosystems 3500Dx Capillary Electrophoresis (CE) platform through the appropriate regulatory process with the China Food and Drug Administration (CFDA) following successful validation.

“Our collaboration with Thermo Fisher Scientific will enable HBM to meet a critical need in the China market for a series of high accuracy kits designed to run on a single CE platform to improve human health outcomes,” said Jianwei Yu, Chairman and CEO of HEALTH BioMed. “Molecular diagnostics such as these can improve diagnosis and treatment strategies in hospital settings while also helping to decrease antibiotic abuse.”

HBM intends to leverage its CE-based Advanced Fragment Analysis (AFA) technology and reagents, which are currently CE-IVD-and cFDA-marked as is the ABI 3500Dx platform, to develop multiple assays under its SureX brand of multiplex kits. HBM’s current offering for human papillomavirus (HPV)screening, for example,is designed to target 25 high- and low-risk markers with high sensitivity, specificity and low hands-on-time. Development of its pharmacogenomics kits under the agreement will be designed to further support precision medicine initiatives in the country.

“As the world leader in serving science, we are proud to be an enabling partner to help HEALTH BioMed build its portfolio of molecular diagnostics designed to better manage human health in China,” said Mark Smedley, president of genetic sciences at Thermo Fisher. “We are committed to working with diagnostic partners around the world who share our vision to drive the era of precision medicine.”

For more information, please visit Thermo Fisher (booths#2334 and #2145) or HEALTH BioMed (booth #2541) during the American Association for Clinical Chemistry (AACC) 2016 annual meeting July 31-Aug. 4 at the Pennsylvania Convention Center in Philadelphia.

 

About HEALTH BioMed and HEALTH Gene Technologies

Founded over 20 years, HEALTH BioMed (HBM) is a leading healthcare provider for clinical diagnostic and pharmaceutical products with business divisions of R&D, manufacture, sales and service for over 600 hospitals users in China.Guided by operation philosophy ‘Health Technologies, Healthier Services’, HBM dedicates to provide the world-class healthcare service and products to our customers.HEALTH Gene Technologies, HBM’s wholly-owned subsidiary, is committed to developing and manufacturing simple, rapid and effective nucleic acid testing solutions for partners in public safety and precisionmedicine. For more information, please visit HBM: www.nb-health.com/HGT.

 

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

 

Related Web Links:

Business Wire

genomeweb